Timothy Showalter
![Timothy Showalter](https://res.cloudinary.com/pcf/images/w_214,h_300,c_scale/fl_lossy/f_auto,q_auto/v1674666395/Showalter_Timothylow_513891c39/Showalter_Timothylow_513891c39.jpg?_i=AA)
About Timothy Showalter
For prostate cancer patients at higher risk of recurrence after radical prostatectomy (RP), early adjuvant radiation therapy (RT) has been shown in randomized trials to improve PSA-relapse free survival, metastasis-free survival and overall survival. Despite evidence to support adjuvant RT, less than 20% of qualifying patients in the U.S. actually receive this treatment. A national survey conducted by Dr. Showalter and colleagues has previously shown that urologist recommendations for adjuvant RT are influenced by perceptions of RT-related toxicity. The evidence to inform these toxicity estimates is lacking. Therefore, it is essential to bridge this difference by elucidating the real-world complication rates of post-prostatectomy RT, and to critically evaluate the significance of RT timing on the risk of complications. Dr. Showalter’s findings will improve management of high-risk prostate cancer, including the influence of timing after surgery, improve cure rates for these patients, and limit complications for lower risk patients.
Award
The 2011 Ben Franklin – PCF Young Investigator Award
Timothy Showalter, MD
University of Virginia
Mentors
Adam Dicker, MD, PhD and Theresa Hyslop, PhD